[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346429-105":59,"doc-detail-346429-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tet1-suppresses-hepatocellular-carcinoma-progression-by-modulating-the-pi3kakt-signaling-pathways","TET1 suppresses hepatocellular carcinoma progression by modulating the PI3K/Akt signaling pathways","","Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor outcomes, motivating the search for new therapeutic targets. This study evaluates TET1, an epigenetic regulator linked to active DNA demethylation, and finds TET1 markedly upregulated in HCC tissues. Higher TET1 expression correlates with advanced tumor stage, worse overall survival, and shorter disease-free survival. Knockdown experiments suppress proliferation, trigger apoptosis, and induce G1-phase arrest, with effects driven by PI3K/Akt pathway activation. TET1 is proposed as a prognostic biomarker and potential therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tet1-suppresses-hepatocellular-carcinoma-progression-by-modulating-the-pi3kakt-signaling-pathways/346429/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tet1-suppresses-hepatocellular-carcinoma-progression-by-modulating-the-pi3kakt-signaling-pathways/346429.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does TET1 play in hepatocellular carcinoma progression?","Question",{"text":112,"@type":113},"TET1 is significantly upregulated in HCC and promotes tumor progression. Higher TET1 levels are associated with advanced stage and poor survival outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does TET1 knockdown affect HCC cells?",{"text":117,"@type":113},"TET1 knockdown suppresses HCC cell proliferation, induces apoptosis, and triggers G1-phase cell cycle arrest.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling pathway mediates TET1’s oncogenic effects?",{"text":121,"@type":113},"TET1’s effects are mediated through activation of the PI3K/Akt signaling pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346429,1790782449,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTET1 suppresses hepatocellular carcinoma progression by modulating the PI3K/Akt signaling pathways  \nShuaiyong Qi1, Ming Chen2, Zhixian Ding1, Mike Dai1, Lusheng Wang1, Jie Chen1, Yu Tang1, Mengxue Hu1, Yafei Li1, Kemeng Tan1, Lili Li1, Hui Jiang2􀀍 & Heng Tang1􀀍  \nHepatocellular carcinoma (HCC) is a highly aggressive malignancy with a poor prognosis, underscoring the urgent need to identify novel therapeutic targets. The epigenetic regulator TET1, a key enzyme involved in active DNA demethylation, has been implicated in various cancers, however, its precise role in HCC remains controversial and poorly defined. This study demonstrates that TET1 is significantly upregulated in HCC tissues, and elevated TET1 expression is associated with advanced tumor stage, shorter overall survival and reduced disease-free survival in patients. Functional assays revealed that TET1 knockdown significantly suppressed HCC cell proliferation and induced apoptosis; it also triggered G1-phase cell cycle arrest. Mechanistically, we found that the oncogenic effects ofTET1 are mediated through activation of the PI3K/Akt signaling pathway. In summary, our results establish TET1 as a critical promoter of HCC progression and elucidate its role in regulating the PI3K/Akt pathway. These findings highlight its value as both a prognostic biomarker and a potential therapeutic target in HCC.  \nKeywords TET1, Hepatocellular carcinoma, PI3K/Akt, Prognosis  \nAmong all malignancies, HCC ranks third in terms of mortality and sixth in terms of incidence worldwide1. Eighty to ninety percent of cases of primary liver cancer are HCC, the main histologic subtype2. With over 72.5% of new cases and 72.7% of deaths happening in the Asia–Pacific region, there are significant geographic disparities in the distribution of HCC, making it a significant public health concern in this region3. The majority of HCC patients are discovered at advanced stages because to its sneaky onset, and only a small percentage are eligible for curative therapy, which contributes to an overall dismal prognosis4. The complicated, multi-step process of hepatocarcinogenesis is fueled by the gradual accumulation of genetic and epigenetic changes. Together, these molecular mechanisms result in the activation of oncogenes, the inactivation of tumor suppressor genes, and eventually broad disruption of basic cellular functions5. HCC is a unique clinical problem due to its high rates of recurrence and mortality despite improvements in clinical care6. Finding useful molecular biomarkers is crucial for directing customized treatment plans because HCC is associated with significant biological heterogeneity and uncertain clinical outcomes. A recent clinicopathological study involving 96 HCC patients detected high expression of Vav1 protein in tumor tissues through immunohistochemistry, and its high expression was significantly associated with poor tumor differentiation, advanced TNM stage, and high recurrence rates 7. Cox regression analysis further confirmed that Vav1 is an independent adverse prognostic factor affecting the 5-year overall survival rate, suggesting that Vav1 could serve as a potential prognostic biomarker for HCC and provide new evidence for postoperative recurrence risk assessment. Beyond clinicopathological indicators, multi-omics studies have revealed the association between metabolic abnormalities and prognosis in HCC. An integrated proteomic and transcriptomic analysis found that KIF5B is closely related to metabolic reprogramming in HCC, and both its protein and mRNA upregulation are significantly associated with poor prognosis8. Mechanistic studies showed that KIF5B activates the AKT/mTOR pathway and reprograms triglyceride metabolism (upregulating FASN and SCD1), promoting HCC cell proliferation and migration. In vitro and in vivo knockdown of KIF5B significantly inhibited tumor growth, indicating its dual r","cbCaidsRdfAWmDvd","https://ap.wps.com/l/cbCaidsRdfAWmDvd","pdf",7952375,13,"English","# Background\n# Methods and functional findings\n# Mechanistic link to PI3K/Akt signaling\n# Clinical implications","[{\"question\":\"What role does TET1 play in hepatocellular carcinoma progression?\",\"answer\":\"TET1 is significantly upregulated in HCC and promotes tumor progression. Higher TET1 levels are associated with advanced stage and poor survival outcomes.\"},{\"question\":\"How does TET1 knockdown affect HCC cells?\",\"answer\":\"TET1 knockdown suppresses HCC cell proliferation, induces apoptosis, and triggers G1-phase cell cycle arrest.\"},{\"question\":\"Which signaling pathway mediates TET1’s oncogenic effects?\",\"answer\":\"TET1’s effects are mediated through activation of the PI3K/Akt signaling pathway.\"}]","TET1 suppresses hepatocellular carcinoma progression by modulating the PI3K/Akt signaling pathways | PDF",1790061422,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8f506762cc8a071b7ab1b7d55ff54fd.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/293447c30c76494c8d430ab55d26b24b.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39d05b1f80ad15ec0775e94d9c5fff07.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d8420b5f15f76ff1dbc8a714bf0aafa.webp",980,1287]